VRTX · News · 20260814N

Guidance / Outlook

VERTEX PHARMACEUTICALS INC / MA · 2026-08-14 · Importance 75 · Surprise 60 · In source text

Vertex raised its full-year 2026 revenue guidance to $13.1 billion-$13.2 billion. The revised outlook reflects stronger reported performance during 2026. The updated range implies continued annual revenue growth from the company’s commercial portfolio.

Key facts

Impact estimates

metricdirectionstageexpectedbasis
revenuepositiveprobable—Vertex raised its full-year 2026 revenue guidance to US$13.1 billion to US$13.2 billion.